Late puberty associated with osteoporosis, bone weakness later in life

Experiencing a growth spurt in the late-teens that ends with peak bone mass might make a person more prone to bone fractures and osteoporosis as they age.
Source: Health News - - Category: Consumer Health News Source Type: news

Related Links:

This meta-analysis examines randomized placebo-controlled clinical trials of drug treatments, particularly treatment with bisphosphonates, for the prevention of fracture in patients with osteoporosis to assess whether these treatments are associated with reduced overall mortality rates.
Source: JAMA Internal Medicine - Category: Internal Medicine Source Type: research
We report a case of bilateral AFFs. The surgical treatments were the same, but the final treatment outcomes were different with or without teriparatide treatment. We investigated the potential causes of the different outcomes of AFFs between the two sides to inform the clinical treatment of AFFs.
Source: Osteoporosis International - Category: Orthopaedics Source Type: research
AbstractPurpose of ReviewBone and muscle mass increase in response to mechanical loading and biochemical cues. Bone-forming osteoblasts differentiate into early osteocytes which ultimately mature into late osteocytes encapsulated in stiff calcified matrix. Increased muscle mass originates from muscle stem cells (MuSCs) enclosed between their plasma membrane and basal lamina. Stem cell fate and function are strongly determined by physical and chemical properties of their microenvironment, i.e., the cell niche.Recent FindingsThe cellular niche is a three-dimensional structure consisting of extracellular matrix components, si...
Source: Current Osteoporosis Reports - Category: Orthopaedics Source Type: research
Authors: Bilezikian JP, Hattersley G, Mitlak BH, Hu MY, Fitzpatrick LA, Dabrowski C, Miller PD, Papapoulos SE Abstract Objective: To evaluate, post hoc, the efficacy and safety of abaloparatide by degree of renal impairment. Methods: ACTIVE was a phase 3, 18-month, randomized, double-blind, active-comparator, placebo-controlled study of postmenopausal women with osteoporosis who received subcutaneous abaloparatide 80 µg, placebo, or open-label teriparatide 20 µg daily. Patients with serum creatinine>2.0 mg/dL or 1.5-2.0 mg/dL with an estimated glomerular filtration rate (eGFR)
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
Publication date: Available online 16 August 2019Source: Clinica Chimica ActaAuthor(s): Yoshiki Nishizawa, Masakazu Miura, Shoichi Ichimura, Masaaki Inaba, Yasuo Imanishi, Masataka Shiraki, Junichi Takada, Osamu Chaki, Hiroshi Hagino, Masao Fukunaga, Saeko Fujiwara, Takami Miki, Noriko Yoshimura, Hiroaki Ohta, from the Japan Osteoporosis Society Bone Turnover Marker Investigation CommitteeAbstractWith the aging of society, the number of osteoporosis-related fractures is increasing. Prevention of osteoporosis and maintenance of the quality of life of osteoporosis patients require early diagnosis, effective treatment, and hi...
Source: Clinica Chimica Acta - Category: Laboratory Medicine Source Type: research
The objective of this review is to summarize the molecular mechanisms of inflammation and oxidative stress activated by Cd at the bone level, particularly in osteoporosis, RA, and OA. Cadmium can increase bone resorption, affect the activity of osteoclasts and calcium (Ca) absorption, and impair kidney function, which favors the development of osteoporosis. In the case of RA, Cd interferes with the activity of antioxidant proteins, like superoxide dismutase (SOD) and catalase (CAT). It also promotes an inflammatory state, inducing the process of citrullination, which affects the proteins of immune response. On the other ha...
Source: Environmental Toxicology and Pharmacology - Category: Environmental Health Source Type: research
This study constructedBacillus subtilis strains for high ‐titer production of MK‐7 through metabolic engineering approaches. InB. subtilis, MK ‐7 biosynthesis was categorized into five modules: glycerol dissociation pathway, shikimate pathway, pyrimidine metabolic pathway, methylerythritol phosphate pathway, and MK‐7 pathway. Overexpression of GlpK and GlpD (glycerol dissociation pathway) led to a ~10% increase in the MK‐7 titer. Del etion of the genesmgsA andaraM increased the MK ‐7 production by 15%. Furthermore, overexpression of AroGD146N (shikimate pathway), PyrGE156K (pyrimidine metabolic pathway), HepS (...
Source: AIChE Journal - Category: Science Authors: Tags: BIOMOLECULAR ENGINEERING, BIOENGINEERING, BIOCHEMICALS, BIOFUELS, AND FOOD Source Type: research
AbstractSummaryEffects of anti-osteoporosis medications such as anti-resorptive and anabolic agents on healing of osteoporotic spinal fracture were retrospectively investigated. The use of anabolic agent significantly enhanced fracture healing, reduced progressive collapse, and presented good pain relief. These findings suggest that proper selection of medication could improve initial management of acute osteoporotic spinal fractures (OSFs).IntroductionAlthough anti-osteoporosis medications have beneficial effects on prevention of osteoporotic spinal fractures (OSFs), few studies have compared effects of medications on fra...
Source: Osteoporosis International - Category: Orthopaedics Source Type: research
Authors: Minkowitz B, Sawyer A, Fung EB, Dvorzhinskiy A, Lane JM Abstract Vitamin D is necessary for the regulation of calcium and phosphate in the human body. Decreased vitamin D levels can alter the bone mineralization process. The prevalence of vitamin D deficiency in the general population is high, and low vitamin D levels are associated with disorders such as rickets and osteoporosis. As knowledge about vitamin D metabolism increases, physicians of all specialties are becoming more attentive to the vitamin D status of their patients. Similarly, orthopaedic surgeons, through various initiatives such as "Ow...
Source: Instructional Course Lectures - Category: Orthopaedics Tags: Instr Course Lect Source Type: research
Date of service: 7/3/2019 A 66-year-old woman with age-related osteoporosis returns to the office for her third denosumab injection. Her last denosumab injection was on Feb. 5, 2019; she had rescheduled her last injection, because she was out of the country in January, when it was due. She is post-menopausal. Her last dual-energy X-ray absorptiometry... [Read More]
Source: The Rheumatologist - Category: Rheumatology Authors: Tags: Billing/Coding From the College denosumab Source Type: research
More News: Health | Orthopaedics | Osteoporosis